Brief Overview of Immuno-Oncology in HCC
Bruno Sangro, MD, PhD
Immunotherapy Combinations in First-line Advanced HCC: Current Evidence and Ongoing Trials
Ghassan Abou-Alfa, MD
Immunotherapy Combinations in Early or Intermediate-Stage HCC: Current Evidence and Ongoing Trials
Peter Galle, MD, PhD
Putting It All Together: Case Discussions
Final Thoughts and Audience Question and Answer Session
Ghassan Abou-Alfa, MD, MBA
Memorial Sloan Kettering Cancer Center
New York, New York
Peter Galle, Other
First Department of Internal Medicine
University Medical Center
Bruno Sangro, MD, PhD
Professor of Medicine
Liver Unit and HPB Oncology Area
Universidad de Navarra
The goal of this activity is to improve the knowledge and competence of learners to integrate currently available and emerging immune checkpoint inhibitor–based therapies for treatment of HCC.
This program is intended for global medical oncologists, hepatologists, and other healthcare providers who care for patients with HCC.
Upon completion of this activity, participants should be able to:
- Identify patients with HCC most likely to benefit from immune checkpoint inhibitor–based combination therapy based on tumor characteristics, previous treatment, and patient characteristics and preferences
- Evaluate clinical data on the use of immune checkpoint inhibitor–based treatment approaches for patients with early or intermediate-stage HCC
- Plan optimal, individualized therapy approaches using immune checkpoint inhibitor–based regimens for patients with advanced or metastatic HCC, as clinically appropriate
- Develop strategies to identify and mitigate unique adverse events associated with immune checkpoint inhibitor therapy in patients with HCC
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.